Most people have heard of BRCA. But cancer genetic testing in India goes far deeper than one test, and understanding the complete picture could change everything about how your cancer is treated.
Let’s start with a confession.
When most people hear “cancer genetic testing,” they think of two things: Angelina Jolie and BRCA. And while Angelina Jolie’s 2013 New York Times op-ed did more for cancer genetics awareness than a decade of medical conferences ever could; the field has moved so far beyond those two genes that BRCA now feels like the opening chapter of a very long book.
A book, it turns out, that most patients never get to read.
This is that book. Or at least a very good summary of it, including what these tests cost, what they actually find, and why in 2026, ordering only a BRCA test is no longer good enough.
Why Cancer Genetic Testing in India Matters More Than Ever
Cancer is, at its most fundamental level, a disease of DNA. Something goes wrong in the genetic code, sometimes inherited from a parent, sometimes acquired over a lifetime and cells that should know when to stop growing, don’t.
Understanding what went wrong, and which specific genes are involved, has transformed oncology from a field that treated cancer by type (“you have breast cancer, here is the breast cancer treatment”) to one that increasingly treats cancer by biology (“your tumour carries this specific mutation, here is the therapy designed for it”).
The result: patients who receive genomically-guided treatment consistently fare better than those who don’t.
A 2024 analysis across multiple solid tumour types found that patients with actionable genomic alterations who received matched targeted therapy had significantly improved progression-free survival compared to those on unmatched therapy. The science is not theoretical anymore. Cancer genetic testing in India, and globally saves lives when it finds what it’s looking for.
The operative phrase being: when it finds what it’s looking for.
The Two Types of Genetic Testing: And Why the Difference Matters
Before we go any further, let’s clear up a confusion that trips up patients and sometimes even their doctors.
There are two fundamentally different types of cancer genetic testing, and they answer completely different questions:
| Germline Testing | Somatic / Tumour Profiling | |
| What it tests? | DNA from blood or saliva- your inherited genetic code | DNA from the tumour itself
|
| What it finds | Inherited mutations you were born with | Mutations the tumour acquired – driving growth and behaviour |
| Who it affects | You and potentially your blood relatives | You and your treatment plan |
| Examples
|
BRCA1/2, Lynch Syndrome, PALB2 – hereditary cancer panel test | KRAS, EGFR, TP53, HER2, TMB, MSI, HRD – tumour profiling test |
Most people who hear “genetic testing for cancer” think of germline testing – the hereditary kind. But in oncology, somatic tumour profiling is equally, often more, clinically important; because it tells oncologists exactly what mutations are driving the cancer right now and which therapies are most likely to work against them.
Ideally, patients get both.
Ironically enough, in practice, many get neither.
What Does a BRCA Test Cost in India- And Is It Worth It?
Now, lets talk about the most important thing in the world, no not love…I m talking about money. Let’s address the question that brings most people to this topic in the first place.
BRCA test cost in India varies significantly depending on the type of testing and the laboratory:
- Single-gene BRCA1/2 sequencing: ₹8,000-₹25,000 depending on the lab and whether it covers both genes
- Hereditary cancer panel test (covering BRCA1, BRCA2, PALB2, CHEK2, ATM, and other high-risk genes): ₹25,000-₹60,000
- Comprehensive Genomic Profiling (CGP) covering 1,080 genes including all hereditary risk genes + somatic tumour drivers: varies by platform
The more important question, however, is not what the BRCA test cost in India is; but whether a standalone BRCA test is the right test to order in the first place.
Most of the people are ready to even go for expensive tests. But the question arises : Is it worth it?
Because here is what a BRCA-only test does not tell you:
- Whether you carry mutations in PALB2, CHEK2, ATM, RAD51C, or dozens of other genes that also significantly elevate cancer risk.
- Whether your tumour has HRD – a DNA repair defect that makes it vulnerable to PARP inhibitors even with normal BRCA genes.
- Whether your tumour carries actionable KRAS, EGFR, or TP53 mutations that would unlock targeted therapies.
- Whether you are at risk of severe toxicity from chemotherapy due to DPYD or UGT1A1 variants.
A BRCA test costs less than a comprehensive panel. But if it misses the answer that changes your treatment, the cost is incalculable.
Because life is invaluable.
Beyond BRCA- The Genes You Actually Need to Know
1. TP53 -The Most Mutated Gene in Human Cancer
If BRCA is the celebrity of cancer genetics, TP53 is the overworked A-list actor that appears in every film but somehow never gets top billing.
TP53 is mutated in approximately 50% of all human cancers – making it the most frequently altered gene in oncology. It encodes a protein called p53, often described as “the guardian of the genome” – a tumour suppressor that, when functioning normally, detects DNA damage and either repairs it or triggers cell death.
When TP53 is mutated, that guardian goes off duty. And the consequences are significant.
Our AACR 2026 late-breaking research – across 1,187 patients with breast, colorectal, and lung cancers; demonstrated that not all TP53 mutations are equal. Gain-of-function mutations behave differently from loss-of-function mutations, associated with higher TMB, greater PD-L1 expression, distinct metastatic patterns, and significantly worse prognosis.
A report that says “TP53 mutation detected” is giving you the headline without the story. The story is in the mutation class; and that level of detail requires comprehensive genomic profiling, not a basic panel.
2. KRAS – The Gene That Was “Undruggable” for 40 Years
KRAS mutations drive approximately 25% of all cancers and for four decades, the field accepted that KRAS was simply undruggable. We accepted the defeat.
Then ASCO 2026 delivered the field’s most dramatic KRAS moment yet: daraxonrasib nearly doubling survival in metastatic pancreatic cancer, with a 60% reduction in risk of death.
KRAS is druggable!!! We won!
The question now is which specific variant a patient carries. KRAS G12C, G12D, G12V – these are not interchangeable. A tumour profiling test that simply reports “KRAS mutated” without specifying the variant is, respectfully, not doing its job.
3. EGFR – The Gold Standard of Targeted Therapy Success
EGFR mutations are present in approximately 15% of NSCLC patients in Western populations and up to 50% in Asian populations. This makes genomic testing for lung cancer one of the most clinically impactful uses of molecular profiling today; because patients with EGFR mutations who receive matched targeted therapy have dramatically better outcomes than those on standard chemotherapy.
But EGFR is also a masterclass in why resistance testing matters. Most patients on first-line EGFR-targeted therapy eventually develop resistance; often through a secondary EGFR mutation (T790M), MET amplification, or HER2 amplification. The EGFR mutation test cost in India ranges from ₹5,000–₹15,000 for single-gene testing – but ordering it alone misses every other driver and resistance mechanism a comprehensive panel would catch.
Understanding resistance, which requires repeat comprehensive profiling at progression, determines which second-line therapy works. This is why a ctDNA test from liquid biopsy, with its ability to re-profile tumour DNA from blood non-invasively, is transforming EGFR management in NSCLC.
4. HRD – The Biomarker Hiding in Plain Sight
Homologous Recombination Deficiency (HRD) is detectable through genomic profiling even when BRCA1/2 are completely normal. It predicts response to PARP inhibitors and platinum-based therapy across multiple cancer types, and it is being underdiagnosed at scale because a standard BRCA test was never designed to find it.
This is why HRD test results should always be interpreted alongside; not instead of: BRCA results. Our analysis of 642 pan-cancer patients found no significant correlation between high HRD scores and BRCA1/2 mutations; confirming that HRD testing and BRCA testing answer different questions.
Both are needed. Neither replaces the other.
5. MSI and MMR – Your Immunotherapy Passport
Microsatellite Instability (MSI) and Mismatch Repair deficiency (dMMR) are perhaps the most directly actionable biomarkers in oncology today – an immunotherapy passport, regardless of cancer type.
Patients with MSI-high or dMMR tumours across virtually any solid tumour are eligible for pembrolizumab – one of the first truly histology-agnostic treatment approvals in oncology.
Yet in our endometrial cancer research, 20% of patients had high MSI scores – and none had been offered immunotherapy.
We had the magic potion and we didn’t used it. What a waste.
The test wasn’t done. The therapy wasn’t considered.
That’s not a clinical failure. It’s a testing failure that comprehensive profiling corrects.
6. TMB – Quantity Over Quality (Sometimes)
Tumour Mutational Burden (TMB) measures mutations per megabase in a tumour’s genome. TMB-high status (≥10 mutations per megabase) earned FDA approval as a companion diagnostic for pembrolizumab in solid tumours, but the story is nuanced. It should be interpreted alongside MSI, PD-L1, and tumour biology rather than in isolation.
The key point: TMB requires sequencing a sufficient number of genes to calculate meaningfully. You simply cannot generate a reliable TMB score from a 20-gene panel.
This is, hands down, one of the strongest clinical arguments for comprehensive genomic profiling over targeted single-gene testing.
7. Pharmacogenomics: The Layer Most Oncologists Aren’t Discussing Yet
Pharmacogenomics (PGx) analyses genetic variants that determine how a patient’s body metabolises specific drugs and it affects every patient who receives chemotherapy.
Three examples clinically significant right now:
- DPYD variants predict toxicity to 5-FU and capecitabine. In our ASCO 2025 pharmacogenomic study of 124 patients using OncoIndx®, patients with specific DPYD variants faced dramatically increased risk of severe adverse events at standard dosing. Pre-treatment testing can prevent life-threatening toxicity.
- UGT1A1 variants predict severe neutropenia and diarrhoea from irinotecan-based regimens at standard doses.
- TYMS variants affect response and toxicity to fluoropyrimidine-based therapy.
Across 36 pharmacogenomic markers in our OncoIndx® panel, patients at risk of toxicity were identified before treatment began. The technology exists. The clinical implementation, in most Indian centres, does not yet.
What Does Comprehensive Genomic Profiling Cost in India – And What Do You Get?
The cancer genetic testing cost in India for comprehensive genomic profiling varies by platform and panel; but the clinical value proposition is straightforward:
A single comprehensive panel like OncoIndx® – covering 1,080 genes, whole-transcriptome RNA sequencing, and protein profiling; replaces the cost and time of sequentially ordering:
- A BRCA test
- An EGFR mutation test
- An NGS test for cancer mutations
- An HRD test
- An MSI/MMR test
- A TMB assessment
- A pharmacogenomics panel
- A hereditary cancer panel test
Each of these ordered separately adds cost, consumes tissue, and critically takes time that cancer patients don’t always have.
A liquid biopsy test in India from a platform like OncoIndx® adds the ability to profile the tumour from blood, capturing the complete genomic landscape without a repeat biopsy.
This is precision oncology in India: finally- at the level the science has always demanded.
Comprehensive Genomic Profiling vs. Single-Gene Testing; Why It’s Not Even Close
Single-gene testing is like reading a book one random page at a time. You might find the important plot point. You might miss it entirely. And you will definitely miss the subplot that turns out to matter most.
Comprehensive genomic profiling reads the whole book in one sitting. A CGP panel like OncoIndx® – covering 1,080 genes on a Whole Exome Sequencing backbone, with whole-transcriptome RNA sequencing and protein profiling integrated, analyses SNVs, indels, copy number variants, fusions, HRD, TMB, MSI, 36 PGx markers, and 350 resistance genes in a single test. From a single specimen. In 12 days.
The clinical argument for CGP over sequential single-gene testing is simple:
- Time. Cancer doesn’t wait. Ordering EGFR first, then ALK, then ROS1, then MET – while your patient is progressing; costs weeks and sometimes lives.
- Tissue. CGP from a single specimen preserves tissue and eliminates the need for multiple invasive procedures.
- Discovery. The actionable finding might not be in the gene you thought to order. The unexpected FGFR2 fusion. The co-occurring HRD score. The pharmacogenomic variant that should have changed the chemotherapy dose from day one. CGP finds these. Sequential testing cannot.
The Three Questions That Change Everything
If you take nothing else from this piece, take these three questions to your next oncology appointment:
- “Has my tumour been comprehensively profiled – not just for specific genes, but across a broad panel including fusions, HRD, TMB, MSI, and pharmacogenomics?”
- “Has my germline DNA been tested with a hereditary cancer panel – not just BRCA1 and BRCA2?”
- “Based on my molecular profile, am I eligible for targeted therapies, immunotherapies, or minimal residual disease testing during follow-up?”
These are not aggressive questions. They are not challenging your oncologist. They are the questions that genomic medicine has made it possible and important, to ask.
BRCA Was Just the Introduction. Time to Read the Rest.
Cancer genetic testing in India in 2026 is not a niche service for elite hospitals. It is a clinical necessity– for every patient with advanced cancer, every patient with a strong family history, and increasingly every patient at diagnosis.
The BRCA test cost in India is just the starting point of a much larger conversation. The complete picture – across 1,080 genes, three biological layers, and every clinically actionable marker; is what OncoIndx® was built to deliver.
Because every tumour has a story worth reading in full.
